Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2022-05-31 Proxy Solicitation & In…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于召开2022年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2022 first extraordinary general meeting (临时股东大会) of Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It includes details about the meeting date, voting methods (onsite and online), registration procedures, agenda items, and proxy forms. There is no financial data, earnings information, or report content. The document is an announcement informing shareholders about the meeting and how to participate and vote. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document length is 4073 characters, which is consistent with a detailed meeting notice and proxy materials. Therefore, the correct classification is PSI with high confidence.
2022-05-31 Chinese
关于新型冠状病毒突变株mRNA疫苗研究战略合作进展的补充公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding a strategic cooperation progress update on mRNA vaccine research. It details a capital increase investment of 40 million RMB into a new subsidiary for vaccine development, including the terms, rationale, and phased funding schedule. The document is relatively short (1905 characters) and focuses on disclosing a financing and strategic cooperation update rather than presenting financial statements or detailed financial results. It does not contain financial performance data or comprehensive financial analysis. Therefore, it is best classified as a Capital/Financing Update (CAP).
2022-05-17 Chinese
关于新型冠状病毒突变株mRNA疫苗研究战略合作进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the progress of a strategic cooperation on mRNA vaccine research. It details the signing of a cooperation agreement, the purpose, content, and risks of the collaboration, and investment details. The document is a formal announcement about a strategic cooperation progress, not a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data. The length is under 5,000 characters and it is a standalone announcement about a strategic cooperation progress, not a report publication or certification. Therefore, it fits best under the category of Capital/Financing Update (CAP) as it involves investment and capital increase in a subsidiary related to the project.
2022-05-16 Chinese
2021年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the implementation of the 2021 annual equity distribution (dividend payment) by Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It details the dividend per share, the adjusted share base due to share repurchases, dividend payment dates, and related procedural information. It references the shareholders' meeting approval and the dividend distribution plan but does not contain full financial statements or comprehensive financial performance data. The document is focused on the dividend amount, payment method, and related shareholder information, which fits the definition of a Notice of Dividend Amount (DIV). The document length is 3444 characters, which is relatively short and consistent with a dividend announcement rather than a full annual report or interim report. Therefore, the appropriate classification is DIV with high confidence.
2022-05-09 Chinese
关于回购公司股份进展情况的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the progress of the company's share repurchase plan. It details the number of shares repurchased, the price range, total amount spent, compliance with regulatory rules, and timing of the repurchase activities. It does not contain financial statements or comprehensive financial data, but rather updates on the share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buying back or selling its own shares. The document length is short (1451 characters) and it is not a report publication announcement or regulatory filing. Therefore, the correct classification is POS with high confidence.
2022-05-06 Chinese
2022年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '安徽安科生物工程(集团)股份有限公司 2022 年第一季度报告全文' which translates to 'Anhui Anke Biological Engineering (Group) Co., Ltd. 2022 First Quarter Report Full Text'. It contains detailed financial data including consolidated balance sheets, profit and loss statements, cash flow statements, and explanations of financial metrics for the first quarter of 2022. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of quarterly financial statements and detailed financial analysis confirms this is an Interim / Quarterly Report. There is no indication that this is an annual report, audit report, or other filing type. Therefore, the correct classification is Interim / Quarterly Report (IR). Q1 2022
2022-04-27 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.